Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease

Molecular Neurobiology

Volumn 45, Issue 1, 2012, Pages 173-185

  Navailles, Sylvia ^a   De Deurwaerdère, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Dopamine release; High frequency stimulation of the subthalamic nucleus; l DOPA; Parkinson's disease; Serotonin function; Serotonin release

Indexed keywords

DOPAMINE; LEVODOPA; SEROTONIN;

ANXIETY DISORDER; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DEPRESSION; GOLD STANDARD; MOOD DISORDER; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC TRANSMISSION; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; SURGICAL APPROACH; SURGICAL TECHNIQUE;

EID: 84856705997     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-011-8230-0     Document Type: Article

References (181)

1. E Melamed J Zoldan G Friedberg I Ziv A Weizmann 1996 Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy Adv Neurol 69 545 550 8615179 1:CAS:528:DyaK2sXmsFGqur8%3D
2. WM McDonald IH Richard MR DeLong 2003 Prevalence, etiology, and treatment of depression in Parkinson's disease Biol Psychiatry 54 363 375 12893111 10.1016/S0006-3223(03)00530-4 (Pubitemid 37267863)
3. E Tandberg JP Larsen D Aarsland JL Cummings 1996 The occurrence of depression in Parkinson's disease. A community-based study Arch Neurol 53 175 179 8639068 1:STN:280:DyaK283isFOiug%3D%3D 10.1001/archneur.1996.00550020087019 (Pubitemid 26055265)
4. AG Schuurman M van den Akker KT Ensinck JF Metsemakers JA Knottnerus AF Leentjens F Buntinx 2002 Increased risk of Parkinson's disease after depression: a retrospective cohort study Neurology 58 1501 1504 12034786 1:STN:280:DC%2BD383ptlOntA%3D%3D (Pubitemid 34552956)
5. M Shiba JH Bower DM Maraganore SK McDonnell BJ Peterson JE Ahlskog DJ Schaid WA Rocca 2000 Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study Mov Disord 15 669 677 10928577 1:STN:280:DC%2BD3M%2FotlWrtQ%3D%3D 10.1002/1531-8257(200007)15:4<669::AID- MDS1011>3.0.CO;2-5 (Pubitemid 30479619)
6. KL Eskow Jaunajars M Angoa-Perez DM Kuhn C Bishop 2011 Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of L-DOPA treatment Neurosci Biobehav Rev 35 556 564 10.1016/j.neubiorev.2010.06.007 1:CAS:528:DC%2BC3cXhsFCrurrJ
7. Steinbusch HW (1984) Serotonin-immunoreactive neurons and their projections in the CNS. In: Björklund A, Hökfelt T, Kuhar MJ (eds) Handbook of chemical neuroanatomy-classical transmitters and transmitters receptors in the CNS Part II. Elsevier, Amsterdam, pp 68-125
8. SJ Kish 2003 Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 91 39 49 12442662 1:CAS:528:DC%2BD3sXlslyrur0%3D
9. B Scholtissen FR Verhey HW Steinbusch AF Leentjens 2006 Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data J Neural Transm 113 59 73 16252066 1:STN:280: DC%2BD2MnotlertQ%3D%3D 10.1007/s00702-005-0368-3 (Pubitemid 41828957)
10. W Birkmayer JD Birkmayer 1987 Dopamine action and disorders of neurotransmitter balance Gerontology 33 168 171 3653699 1:CAS:528: DyaL1cXjsFyitw%3D%3D 10.1159/000212871 (Pubitemid 17124823)
11. SJ Kish J Tong O Hornykiewicz A Rajput LJ Chang M Guttman Y Furukawa 2008 Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 120 131 17956909
12. B Scatton F Javoy-Agid L Rouquier B Dubois Y Agid 1983 Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease Brain Res 275 321 328 6626985 1:CAS:528:DyaL3sXlsleqsL4%3D 10.1016/0006-8993(83)90993-9 (Pubitemid 13004530)
13. L Kerenyi GA Ricaurte DJ Schretlen U McCann J Varga WB Mathews HT Ravert RF Dannals J Hilton DF Wong Z Szabo 2003 Positron emission tomography of striatal serotonin transporters in Parkinson disease Arch Neurol 60 1123 1129 10.1001/archneur.60.9.1223 (Pubitemid 37099627)
14. M Politis K Wu C Loane L Kiferle S Molloy DJ Brooks P Piccini 2010 Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study Neurobiol Dis 40 216 221 20594979 1:CAS:528:DC%2BC3cXhtVGrt7zL 10.1016/j.nbd.2010.05.028
15. V Caretti D Stoffers A Winogrodzka, et al. 2008 (2008) Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study J Neural Transm 115 721 729 18335163 1:CAS:528:DC%2BD1cXmslyhur4%3D 10.1007/s00702-007-0015-2
16. F Roselli NM Pisciotta M Pennelli MS Aniello A Gigante MF De Caro E Ferrannini B Tartaglione A Niccoli-Asabella G Defazio P Livrea G Rubini 2010 Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study Mov Disord 25 1853 1859 20669272 10.1002/mds.23179
17. M Doder EA Rabiner N Turjanski AJ Lees DJ Brooks 2003 Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study Neurology 60 601 605 12601099 1:CAS:528:DC%2BD3sXptFKktA%3D%3D (Pubitemid 36246076)
18. GM Halliday PC Blumbergs RG Cotton WW Blessing LB Geffen 1990 Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease Brain Res 510 104 107 1691042 1:STN:280:DyaK3c3htlWrtQ%3D%3D 10.1016/0006-8993(90)90733-R (Pubitemid 20060808)
19. KA Jellinger 1991 Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway Mol Chem Neuropathol 14 153 197 1958262 1:CAS:528:DyaK38XkvVOmt7g%3D 10.1007/BF03159935
20. GG Kovacs S Klöppel I Fischer S Dorner E Lindeck-Pozza P Birner IC Bötefür P Pilz B Volk H Budka 2003 Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders Neuroreport 14 73 76 12544834 1:CAS:528:DC%2BD3sXmsVShsw%3D%3D 10.1097/00001756-200301200-00014 (Pubitemid 36160745)
21. U Ungerstedt GW Arbuthnott 1970 Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesion of the nigrostriatal dopamine system Brain Res 24 485 493 5494536 1:STN:280:DyaE3M%2Fotl2msA%3D%3D 10.1016/0006-8993(70)90187-3
22. B Henry AR Crossman JM Brotchie 1998 Characterization of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Exp Neurol 151 334 342 9628768 1:CAS:528:DyaK1cXkt1Kisrs%3D 10.1006/exnr.1998.6819 (Pubitemid 28285913)
23. U Ungerstedt 1971 Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour Acta Physiol Scand Suppl 367 49 68 4332692 1:STN:280:DyaE38%2FovVChtQ%3D%3D
24. T Zetterstrom M Herrera-Marschitz U Ungerstedt 1986 Simultaneous measurement of dopamine release and rotational behaviour in the 6-hydroxydopamine denervated rats using intracerebral dialysis Brain Res 376 1 7 3087581 1:STN:280:DyaL283ksVejsg%3D%3D 10.1016/0006-8993(86)90893-0 (Pubitemid 16046010)
25. M Herrera-Marschitz G Arbuthnott U Ungerstedt 2010 The rotational model and microdialysis: significance for dopamine signalling, clinical studies and beyond Prog Neurobiol 90 176 189 20185033 1:CAS:528:DC%2BC3cXisFOmurY%3D 10.1016/j.pneurobio.2009.01.005
26. RK Pearce M Jackson L Smith P Jenner CD Marsden 1995 Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix Jacchus) Mov Disord 10 731 740 8749992 1:STN:280:DyaK28zmtlegug%3D%3D 10.1002/mds.870100606 (Pubitemid 26039721)
27. MA Cenci KE Ohlin 2009 Rodent models of treatment-induced motor complications in Parkinson's disease Parkinsonism Relat Disord 15 S13 S17 20123549 10.1016/S1353-8020(09)70828-4
28. CW Olanow JA Obeso 2000 Preventing levodopa-induced dyskinesias Ann Neurol 47 Suppl 1 S167 S176 10762145 1:CAS:528:DC%2BD3cXivVOntbc%3D
29. R de la Fuente-Fernandez V Sossi Z Huang S Furtado JQ Lu DB Calne TJ Ruth AJ Stoessl 2004 Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2747 2754 15329355 10.1093/brain/awh290 (Pubitemid 39627382)
30. MA Cenci M Lundblad 2006 Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia J Neurochem 99 381 392 16942598 1:CAS:528: DC%2BD28XhtF2rsLvP 10.1111/j.1471-4159.2006.04124.x (Pubitemid 44477196)
31. MA Cenci 2007 L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment Parkinsonism Relat Disord 13 S263 S267 18267248 10.1016/S1353-8020(08)70014-2 (Pubitemid 351215253)
32. I Perez-Otano MT Herrero C Oset ML De Ceballos MR Luguin JA Obseo J Del Rio 1991 Extensive loss of dopamine and serotonin induced by chronic administration of MPTP in the marmoset Brain Res 567 127 132 1815820 1:CAS:528:DyaK38XltlWrtQ%3D%3D 10.1016/0006-8993(91)91444-6
33. C Pifl G Schingnitz O Hornykiewicz 1991 Effect of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey Neuroscience 44 591 605 1754053 1:CAS:528:DyaK3MXmsFehtLw%3D 10.1016/0306-4522(91)90080-8
34. H Russ W Mihatsch M Gerlach P Riederer H Przuntek 1991 Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett 123 115 118 1712088 1:CAS:528:DyaK3MXhsl2qsb0%3D 10.1016/0304-3940(91)90171-O
35. S Boulet S Mounayar A Poupard, et al. 2008 Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis J Neurosci 28 9575 9584 18799689 1:CAS:528:DC%2BD1cXht1SgtrrI 10.1523/JNEUROSCI.3465-08.2008
36. K Hara I Tohyama H Kimura H Fukuda S Nakamura M Kameyama 1987 Reversible serotoninergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches Brain Res 410 371 374 3297254 1:CAS:528:DyaL2sXksFKrtbk%3D 10.1016/0006-8993(87)90341-6 (Pubitemid 17083337)
37. T Nayyar M Bubser MC Ferguson MD Neely J Shawn Goodwin TJ Montine AY Deutch TA Ansah 2009 Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of beaded serotonin innervation Eur J Neurosci 30 207 216 19659923 10.1111/j.1460-9568.2009.06806.x
38. E Rousselet C Joubert J Callebert K Parain L Tremblay G Orieux JM Launay C Cohen-Salmon EC Hirsch 2003 Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice Neurobiol Dis 14 218 228 14572444 1:CAS:528: DC%2BD3sXot1Grtrk%3D 10.1016/S0969-9961(03)00108-6 (Pubitemid 37311286)
39. MG Vuckovic RI Wood DP Holschneider A Abernathy DM Togasaki A Smith GM Petzinger MW Jakowec 2008 Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury Neurobiol Dis 32 319 327 18718537 1:CAS:528:DC%2BD1cXht1Kns7bI 10.1016/j.nbd.2008.07.015
40. G Rozas I Liste MJ Guerra JL Labandeira-Garcia 1998 Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice Neurosci Lett 245 151 154 9605478 1:CAS:528:DyaK1cXitVKmsr8%3D 10.1016/S0304-3940(98)00198-0 (Pubitemid 28287345)
41. GR Breese AA Baumeister TJ McCown SG Emerick GD Frye K Crotty RA Muller 1984 Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine J Pharmacol Exp Ther 231 343 354 6149306 1:CAS:528:DyaL2MXktVCntQ%3D%3D (Pubitemid 15213843)
42. L Erinoff SR Snodgrass 1986 Effects of adult or neonatal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity, monoamine levels, and response to caffeine Pharmacol Biochem Behav 24 1039 1045 3086901 1:CAS:528:DyaL28XksFGjsr4%3D 10.1016/0091-3057(86)90453-3 (Pubitemid 16074786)
43. ET Iwamoto HH Loh EL Way 1976 Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions Eur J Pharmacol 37 339 356 986305 1:CAS:528:DyaE28XkvVyjsr4%3D 10.1016/0014-2999(76)90042-X
44. FC Zhou S Bledsoe J Murphy 1991 Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain Brain Res 556 108 116 1718555 1:STN:280:DyaK38%2FjsVSjtw%3D%3D 10.1016/0006-8993(91)90553-8
45. DL Commins RA Shaughnessy KJ Axt G Vosmer LS Seiden 1989 Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions J Neural Transm 77 197 210 2503586 1:STN:280:DyaL1MzktFOnug%3D%3D 10.1007/BF01248932 (Pubitemid 19176001)
46. AH Kaya R Vlamings S Tan LW Lim PJ Magill HW Steinbusch V Visser-vanderwalle T Sharp Y Temel 2008 Increased electrical and metabolic activity in the dorsal raphe nucleus of parkinsonian rats Brain Res 1221 93 97 18565496 1:CAS:528:DC%2BD1cXotlCksrY%3D 10.1016/j.brainres.2008.05.019
47. Y Temel LJ Boothman A Blokland PJ Magill HW Steinbusch V Visser-Vandewalle T Sharp 2007 Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus Proc Natl Acad Sci U S A 104 17087 17092 17942692 1:CAS:528: DC%2BD2sXht1KgtLfL 10.1073/pnas.0704144104 (Pubitemid 350210996)
48. S Wang GJ Zhang J Liu ZH Wu T Wang ZH Gui L Chen Y Wang 2009 Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat Neuroscience 159 850 861 19174182 1:CAS:528:DC%2BD1MXisFantLg%3D 10.1016/j.neuroscience.2008.12.051
49. S Wang GJ Zhang J Liu ZH Wu U Ali Y Wang L Chen ZH Gui 2009 The firing of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease Neuroscience 162 1091 1100 19410634 1:CAS:528:DC%2BD1MXps1aitLo%3D 10.1016/j.neuroscience.2009.04.069
50. S Wang QJ Zhang J Liu U Ali ZH Wu L Chen ZH Gui Y Wang YP Hui 2009 In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease Exp Neurol 219 239 248 19500571 1:CAS:528: DC%2BD1MXpvF2mtb8%3D 10.1016/j.expneurol.2009.05.029
51. Y Takeuchi T Sawada S Blunt P Jenner CD Marsden 1991 Serotonergic sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon Brain Res 551 171 177 1680521 1:STN:280: DyaK38%2FgsVOjuw%3D%3D 10.1016/0006-8993(91)90930-T
52. BP Guiard M El Mansari Z Merali P Blier 2008 Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions Int J Neuropsychopharmacol 11 625 639 18205979 1:CAS:528:DC%2BD1cXnvFehtrc%3D (Pubitemid 351931823)
53. BP Bejjani P Damier I Arnulf, et al. 1999 Transient acute depression induced by high-frequency deep-brain stimulation N Engl J Med 340 1476 1480 10320386 1:STN:280:DyaK1M3ktVShug%3D%3D 10.1056/NEJM199905133401905 (Pubitemid 29220547)
54. G Deuschl W Fogel M Hahne, et al. 2002 Deep-brain stimulation for Parkinson's disease J Neurol 249 suppl 3 36 39
55. JL Houeto P Damier PB Bejjani, et al. 2000 Subthalamic stimulation in Parkinson disease Arch Neurol 57 461 465 10768618 1:STN:280: DC%2BD3c3ivFWjtw%3D%3D 10.1001/archneur.57.4.461
56. Tan SK, Hartung H, Visser-Vandewalle V, Steinbusch HW, Temel Y, Sharp T (2011) A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission. Exp Neurol. doi: 10.1016/j.expneurol.2011.08.027
57. S Thobois P Mertens M Guenot, et al. 2002 Subthalamic nucleus stimulation in Parkinson's disease J Neurol 249 529 534 12021940 1:STN:280: DC%2BD38zjsFersw%3D%3D 10.1007/s004150200059 (Pubitemid 34507824)
58. J Kulisevsky ML Berthier A Gironell, et al. 2002 Mania following deep brain stimulation for Parkinson's disease Neurology 59 1421 1424 12427895 1:STN:280:DC%2BD38nmslKltw%3D%3D (Pubitemid 35285998)
59. PK Doshi N Chaya MH Bhatt 2002 Depression leading to attempted suicide after subthalamic nucleus stimulation for Parkinson's disease Mov Disord 17 1084 1100 12360564 10.1002/mds.10198 (Pubitemid 36041019)
60. JL Houeto V Mesnage L Mallet, et al. 2002 Behavioral disorders, Parkinson's disease and subthalamic stimulation J Neurol Neurosurg Psychiatry 72 701 707 12023409 1:STN:280:DC%2BD38zhtFaisg%3D%3D 10.1136/jnnp.72.6.701 (Pubitemid 34557009)
61. JA Saint-Cyr LL Trépanier R Kumar, et al. 2000 Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease Brain 123 2091 2108 11004126 10.1093/brain/123.10.2091
62. S Navailles A Benazzouz B Bioulac C Gross P De Deurwaerdère 2010 High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease J Neurosci 30 2356 2364 20147561 1:CAS:528:DC%2BC3cXkt12ks78%3D 10.1523/JNEUROSCI.5031-09.2010
63. SK Tan ML Janssen A Jahanshahi L Chouliaras V Visser-Vandewalle LW Lim HW Steinbusch T Sharp Y Temel 2011 High frequency stimulation of the subthalamic nucleus increases c-fos immunoreactivity in the dorsal raphe nucleus and afferent brain regions J Psychiatr Res 45 1307 1315 21641003 10.1016/j.jpsychires.2011.04.011
64. B Amilhon E Lepicard T Renoir R Mongeau D Popa O Poirel S Miot C Gras AM Gardier J Gallego M Hamon L Lanfumey B Gasnier B Giros S El Mestikawy 2010 VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety J Neurosci 30 2198 2210 20147547 1:CAS:528:DC%2BC3cXkt12lur0%3D 10.1523/JNEUROSCI.5196-09.2010
65. MW Hale CA Lowry 2011 Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits Psychopharmacology (Berl) 213 243 264 1:CAS:528:DC%2BC3cXhsVersLjI 10.1007/s00213-010-2089-z
66. V Kiyasova SP Fernandez J Laine L Stankovski A Muzerelle S Doly P Gaspar 2011 A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei J Neurosci 31 2756 2768 21414898 1:CAS:528:DC%2BC3MXislGisb8%3D 10.1523/JNEUROSCI.4080-10.2011
67. R McQuade T Sharp 1997 Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis J Neurochem 69 791 796 9231740 1:CAS:528:DyaK2sXkvFGku7Y%3D 10.1046/j.1471-4159. 1997.69020791.x (Pubitemid 27327983)
68. V Gradinaru M Mogri KR Thompson JM Henderson K Deisseroth 2009 Optical deconstruction of parkinsonian neural circuitry Science 324 354 359 19299587 1:CAS:528:DC%2BD1MXksVOlt7Y%3D 10.1126/science.1167093
69. T Sesia V Bulthuis S Tan LW Lim R Vlamings A Blokland HW Steinbusch T Sharp V Visser-Vandewalle Y Temel 2010 Deep brain stimulation of the nucleus accumbens shell increases impulsive behavior and tissue levels of dopamine and serotonin Exp Neurol 225 302 309 20615406 1:CAS:528:DC%2BC3cXhtFCmur7M 10.1016/j.expneurol.2010.06.022
70. H Hartung SK Tan HM Steinbusch Y Temel T Sharp 2011 High-frequency stimulation of the subthalamic nucleus inhibits the firing of juxtacellular labelled 5-HT-containing neurones Neuroscience 186 135 145 21515342 1:CAS:528:DC%2BC3MXntV2lt7g%3D 10.1016/j.neuroscience.2011.04.004
71. GC Cotzias 1968 L-Dopa for Parkinsonism N Engl J Med 278 630 5637779 1:STN:280:DyaF1c7jt1yisQ%3D%3D
72. O Hornykiewicz 1966 Dopamine (3-hydroxytyramine) and brain function Pharmacol Rev 18 925 964 5328389 1:STN:280:DyaF287lsVakuw%3D%3D
73. DW Miller ED Abercrombie 1999 Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine- treated rats J Neurochem 72 1516 1522 10098856 1:CAS:528:DyaK1MXitFCksL0%3D 10.1046/j.1471-4159.1999.721516.x (Pubitemid 29140823)
74. S Sarre N De Klippel P Herregodts G Ebinger Y Michotte 1994 Biotransformation of locally L-dopa in the corpus striatum of the hemi-parkinsonian rats studies with microdialysis Naunyn Schmiedebergs Arch Pharmacol 350 15 21 7935849 1:CAS:528:DyaK2cXlt1Grur4%3D 10.1007/BF00180005 (Pubitemid 24214243)
75. BS Bunney GK Aghajanian RH Roth 1973 Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurons Nat New Biol 245 123 125 4518113 1:CAS:528:DyaE2cXjtlyitg%3D%3D
76. NB Mercuri P Calabresi G Bernardi 1990 Responses of rat substantia nigra compacta neurones to L-DOPA Br J Pharmacol 100 257 260 2165836 1:CAS:528:DyaK3cXkslWitro%3D (Pubitemid 20170639)
77. DG Harden AA Grace 1995 Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment J Neurosci 15 6157 6166 7666198 1:CAS:528:DyaK2MXnvFChtbk%3D
78. T Maeda K Kannari T Suda M Matsunaga 1999 Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum Brain Res 817 185 191 9889362 1:CAS:528:DyaK1MXhslWmsg%3D%3D 10.1016/S0006-8993(98)01248-7 (Pubitemid 29225359)
79. K Lloyd O Hornykiewicz 1970 Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions Science 170 1212 1213 5478194 1:CAS:528:DyaE3MXktVGnsQ%3D%3D 10.1126/science.170.3963.1212
80. K Kannari H Tanaka T Maeda M Tomiyama T Suda M Matsunaga 2000 Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation J Neurochem 74 263 269 10617128 1:CAS:528:DC%2BD3cXlt12l 10.1046/j.1471-4159.2000.0740263.x (Pubitemid 30012777)
81. WY Lee JW Chang NL Nemeth UJ Kang 1999 Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administration in parkinsonian rats J Neurosci 19 3266 3274 10191339 1:CAS:528:DyaK1MXitlGmsrg%3D (Pubitemid 29174018)
82. R Arai N Karasawa I Nagatsu 1995 L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci Lett 195 195 198 8584208 1:CAS:528: DyaK2MXns1Giur8%3D 10.1016/0304-3940(95)11817-G
83. LK Ng TN Chase RW Colburn IJ Kopin 1970 L-Dopa-induced release of cerebral monoamines Science 170 76 77 5452893 1:CAS:528:DyaE3cXltFyrs7Y%3D 10.1126/science.170.3953.76
84. F Tison N Mons M Geffard P Henry 1991 The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain J Neural Transm Park Dis Dement Sect 3 27 39 2064729 1:CAS:528:DyaK3sXltlajtrY%3D 10.1007/BF02251134
85. H Yamada Y Aimi I Nagatsu K Taki M Kudo R Arai 2007 Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulate in parkinsonian model rats Neurosci Res 59 1 7 17586078 1:CAS:528:DC%2BD2sXpsFOjsrY%3D 10.1016/j.neures.2007.05.002 (Pubitemid 47285387)
86. R Arai N Karazawa I Nagatsu 1996 Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study Brain Res 706 177 179 8720509 1:CAS:528: DyaK28XkslKmug%3D%3D 10.1016/0006-8993(95)01281-8
87. LK Ng TN Chase RW Colburn IJ Kopin 1972 L-Dopa in Parkinsonism. A possible mechanism of action Neurology 22 688 696 4673250 1:CAS:528: DyaE38XltlGitrc%3D
88. LK Ng RW Colburn IJ Kopin 1972 Effects of L-dopa on accumulation and efflux of monoamines in particles of brain homogenates J Pharmacol Exp Ther 183 316 325 5083548 1:CAS:528:DyaE3sXpt12nsQ%3D%3D
89. S Navailles B Bioulac C Gross P De Deurwaerdère 2010 Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol Dis 38 136 143 20096781 1:CAS:528: DC%2BC3cXivFKhtL4%3D 10.1016/j.nbd.2010.01.012
90. H Tanaka K Kannari T Maeda M Tomiyama T Suda M Matsunaga 1999 Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 631 634 10208602 1:CAS:528: DyaK1MXisFantL0%3D 10.1097/00001756-199902250-00034 (Pubitemid 29333295)
91. K Kannari H Yamato H Shen M Tomiyama T Suda M Matsunaga 2001 Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation J Neurochem 76 1346 1353 11238719 1:CAS:528: DC%2BD3MXhvVCjtb4%3D 10.1046/j.1471-4159.2001.00184.x (Pubitemid 32198239)
92. HS Lindgren DR Andersson S Lagerkvist H Nissbrandt MA Cenci 2010 L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J Neurochem 112 1465 1476 20050978 1:CAS:528: DC%2BC3cXjsFaku7o%3D 10.1111/j.1471-4159.2009.06556.x
93. H Yamato K Kannari H Shen T Suda M Matsunaga 2001 Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum Neuroreport 12 1123 1126 11338177 1:CAS:528:DC%2BD3MXjs1egurs%3D 10.1097/00001756-200105080- 00015 (Pubitemid 32374729)
94. EC Azmitia M Segal 1978 An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat J Comp Neurol 179 641 667 565370 1:STN:280:DyaE1c7ltFeguw%3D%3D 10.1002/cne.901790311 (Pubitemid 8372646)
95. S Navailles B Bioulac C Gross P De Deurwaerdère 2011 Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol Dis 41 585 590 21092759 1:CAS:528:DC%2BC3MXovFGi 10.1016/j.nbd.2010. 11.007
96. P Seeman 1980 Brain dopamine receptors Pharmacol Rev 32 229 313 6117090 1:CAS:528:DyaL3MXktFOktL0%3D
97. M Carta T Carlsson D Kirik A Björklund 2007 Dopamine released from 5-HT terminal sis the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 1819 1833 17452372 10.1093/brain/awm082 (Pubitemid 47343795)
98. Navailles S, De Deurwaerdère P (2012) Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-DOPA-induced dyskinesia. Parkinson's Disease. doi: 10.1155/2012/323686
99. G Bartholini M Da Prada A Pletscher 1968 Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase J Pharm Pharmacol 20 228 229 4385052 1:CAS:528:DyaF1cXos1SgtQ%3D%3D 10.1111/j.2042-7158.1968.tb09726.x
100. GM Everett JW Borcherding 1970 L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice Science 168 849 850 17768920 1:CAS:528:DyaE3cXksVektLg%3D 10.1126/science.168.3933.849
101. H Tohgi T Abe S Takahashi J Takahashi H Hamato 1993 Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration Neurosci Lett 159 135 138 7505410 1:CAS:528:DyaK2cXmvFeltg%3D%3D 10.1016/0304-3940(93)90817-5 (Pubitemid 23283257)
102. S Gil C Park J Lee H Koh 2010 The roles of striatal serotonin and L: -amino-acid decarboxylase on L: -DOPA-induced dyskinesia in a hemiparkinsonian rat model Cell Mol Neurobiol 30 817 825 20232137 1:CAS:528:DC%2BC3cXpsFKkur0%3D 10.1007/s10571-010-9509-9
103. F Héry G Simonnet S Bourgoin P Soubrié F Artaud M Hamon J Glowinski 1979 Effect of nerve activity on the in vivo release of [3H]serotonin continuously formed from L-[3H]tryptophan in the caudate nucleus of the cat Brain Res 169 317 334 221075 10.1016/0006-8993(79)91033-3 (Pubitemid 9211560)
104. K Thorré S Sarre I Smolders G Ebinger Y Michotte 1998 Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis Brain Res 796 107 116 9689460 10.1016/S0006-8993(98) 00336-9 (Pubitemid 28343239)
105. Navailles S, Carta M, Guthrie M, De Deurwaerdère P (2012) L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. CNS Agents Med Chem (in press)
106. S Navailles P De Deurwaerdère 2011 Presynaptic control of serotonin on striatal dopamine function Psychopharmacology (Berl) 213 213 242 1:CAS:528:DC%2BC3cXhtlSjtbzL 10.1007/s00213-010-2029-y
107. SJ Gil CH Park JE Lee YK Minn HC Koh 2011 Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats Brain Res Bull 84 151 156 21163338 1:CAS:528:DC%2BC3MXhslOnt7g%3D 10.1016/j.brainresbull.2010.12.006
108. M Lundblad S af Bjerkén MA Cenci F Pomerleau GA Gerhardt I Strömberg 2009 Chronic intermittent L-DOPA treatment induces changes in dopamine release J Neurochem 108 998 1008 19196428 10.1111/j.1471-4159.2008. 05848.x 1:CAS:528:DC%2BD1MXisV2htLw%3D
109. H Braak K Del Tredici H Bratzke J Hamm-Clement D Snadmann-Kell U Rub 2002 Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J Neurol 249 Suppl 3 III/1-5 12528692
110. Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ (2011) [(18)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(18)F]FDOPA and [(11)C]DASB PET study in Parkinson's disease. Neuroimage. doi: 10.1016/j.neuroimage.2011.09.034.
111. T Alexander CE Sortwell CD Sladek RH Roth K Steece-Collier 1997 Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors Cell Transplant 6 309 315 9171163 1:STN:280:DyaK2szhsV2ruw%3D%3D 10.1016/S0963-6897(97)00031-6 (Pubitemid 27225181)
112. AN Basma EJ Morris WJ Nicklas HM Geller 1995 L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation J Neurochem 64 825 832 7830076 1:CAS:528:DyaK2MXjtFymt78%3D 10.1046/j.1471-4159.1995.64020825.x
113. N Cheng T Maeda T Kume S Kaneko H Kochiyama A Akaike Y Goshima Y Misu 1996 Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons Brain Res 743 278 283 9017256 1:CAS:528:DyaK28XntlKrurw%3D 10.1016/S0006-8993(96)01056-6 (Pubitemid 27028782)
114. B Pardo MA Mean JG de Yebenes 1995 L-Dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells J Neurochem 64 576 582 7830050 1:CAS:528:DyaK2MXjtFymsL8%3D 10.1046/j.1471-4159. 1995.64020576.x
115. H Hashiguti D Nakahara W Maruyama M Naoi T Ikeda 1993 Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis J Neural Transm Gen Sect 93 213 223 7692885 1:CAS:528: DyaK2cXhsFClsrk%3D 10.1007/BF01244998 (Pubitemid 23272409)
116. DM Kuhn R Arthur Jr 1998 Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons J Neurosci 18 7111 7117 9736634 1:CAS:528:DyaK1cXmt1Sjt74%3D (Pubitemid 28425798)
117. DM Kuhn RE Arthur Jr 1999 L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein Brain Res Mol Brain Res 73 78 84 10581400 1:CAS:528:DyaK1MXns1ahtL8%3D 10.1016/S0169-328X(99)00238-7
118. W Maruyama M Naoi A Takahashi H Watanabe Y Konagaya K Mokuno S Hasegawa D Nakahara 1992 The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies J Neural Transm Gen Sect 90 183 197 1363050 1:CAS:528:DyaK3sXisVOns7o%3D 10.1007/BF01250960 (Pubitemid 23037329)
119. KL Eskow Jaunajars KB Dupre CY Ostock T Button T Deak C Bishop 2010 Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat Behav Pharmacol 21 627 637 10.1097/FBP.0b013e32833e7e80 1:CAS:528:DC%2BC3cXhtFGnsLjI
120. J Cao J Liu QJ Zhang T Wang S Wang LN Han Q Li 2007 The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease Neurosci Bull 23 315 322 18064060 1:CAS:528:DC%2BD1cXht1yktrnF 10.1007/s12264-007-0047-5
121. P De Deurwaerdère MF Chesselet 2000 Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats J Neurosci 20 5170 5178 10864974 (Pubitemid 30421720)
122. 2C receptors, vol The receptors series. Springer, New York
123. SH Fox B Moser JM Brotchie 1998 Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine- lseioned rat model of Parkinson's disease Exp Neurol 151 35 49 9582253 1:CAS:528:DyaK1cXjsV2ntbo%3D 10.1006/exnr.1998.6792 (Pubitemid 28223854)
124. SH Fox JM Brotchie 2000 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease Mov Disord 15 1046 1049 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C
125. ZH Gui QJ Zhang J Liu U Ali Y Wang T Wang L Chen C Hou LL Fan 2010 In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-minduced parkinsonian rats Neuroscience 169 1315 1325 20576497 1:CAS:528:DC%2BC3cXps1Wku7k%3D 10.1016/j.neuroscience.2010.05.059
126. CP Chen JT Alder L Bray AE Kingsbury PT Francis OJ Foster 1998 Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex Ann NY Acad Sci 861 288 289 9928295 1:STN:280:DyaK1M7islamtA%3D%3D 10.1111/j.1749-6632.1998.tb10229.x (Pubitemid 29047755)
127. D Frechilla A Cobreros L Salside R Moratalla R Insausti M Luquin J Del Rio 2001 Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys Synapse 39 288 296 11169778 1:CAS:528:DC%2BD3MXhtVGntbw%3D 10.1002/1098-2396(20010315)39:4<288:: AID-SYN1011>3.0.CO;2-V (Pubitemid 32128650)
128. Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM (2010) Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque Neurobiol Aging, in press.
129. ME Castro J Pascual T Romon J Berciano J Figols A Pazos 1998 5-HT1B receptor binding in degenerative movement disorders Brain Res 290 323 328 10.1016/S0006-8993(97)01566-7 (Pubitemid 28234519)
130. R Quirion J Richard 1987 Differential effects of selective lesion of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain Synapse 1 124 130 3145578 1:CAS:528:DyaL2sXps1OisA%3D%3D 10.1002/syn.890010115 (Pubitemid 17114255)
131. X Zhang PE Andren P Greengard P Svenningsson 2008 Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism Proc Natl Acad Sci U S A 105 2163 2168 18256188 1:CAS:528:DC%2BD1cXisVWmsbY%3D 10.1073/pnas.0711839105 (Pubitemid 351439482)
132. QJ Zhang S Wang J Liu U Ali ZH Gui ZH Wu YP Hui Y Wang L Chen 2010 Unilateral lesion of the nigrostriatal pathway decreases the response of interneurons in medial prefrontal cortex to 5-HT 2A/2C receptor stimulation in the rat Brain Res 1312 127 137 19948151 1:CAS:528:DC%2BC3cXjvVCqtw%3D%3D 10.1016/j.brainres.2009.11.052
133. X Zhang PE Andren P Svenningsson 2007 Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model Physiol Behav 92 29 33 17588622 1:CAS:528:DC%2BD2sXhtVChu7fF 10.1016/j.physbeh.2007.05.033 (Pubitemid 47374252)
134. Y Li XF Huang C Deng B Meyer A Wu Y Yu W Ying GY Yang MA Yenari Q Wang 2010 Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced parkinsonian rats Synapse 64 224 230 19862688 1:CAS:528:DC%2BC3cXkvFKjtQ%3D%3D 10.1002/syn.20722
135. G Riahi M Morissette M Parent T Di Paolo 2011 Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias Eur J Neurosci 33 1823 1831 21501255 10.1111/j.1460-9568.2011.07675.x
136. SH Fox JM Brotchie 2000 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in 6-hydroxydopamine- lesioned rat Eur J Pharmacol 398 59 64 10856448 1:CAS:528:DC%2BD3cXktVSmurk%3D 10.1016/S0014-2999(00)00238-7 (Pubitemid 30336677)
137. QJ Zhang LB Li XL Niu J Liu ZH Gui JJ Feng U Ali YP Hui ZH Wu 2011 The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson's disease Brain Res 1384 69 79 21291871 1:CAS:528:DC%2BC3MXjvV2msr8%3D 10.1016/j.brainres.2011.01.086
138. G Di Giovanni V Di Matteo M Pierucci A Benigno E Esposito 2006 Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies? Curr Med Chem 13 3069 3081 17073648 10.2174/092986706778521805 (Pubitemid 44509709)
139. V Di Matteo M Pierucci E Esposito G Cresimanno A Benigno G Di Giovanni 2008 Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders Prog Brain Res 172 423 463 18772045 10.1016/S0079-6123(08)00921-7 1:CAS:528:DC%2BD1cXhsV2isbjI
140. F Durif M Vidailhet F Assal C Roche AM Bonnet Y Agid 1997 Low-dose clozapine improves dyskinesias in Parkinson's disease Neurology 48 658 662 9065543 1:CAS:528:DyaK2sXit12rtbc%3D (Pubitemid 27120102)
141. K Ikeguchi A Kuroda 1995 Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs Eur Arch Psychiatry Clin Neurosci 244 320 324 7772616 1:STN:280:DyaK2M3ptVGisw%3D%3D 10.1007/BF02190411
142. SL Nicholson JM Brotchie 2002 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy Eur J Neurol S3 1 6 10.1046/j.1468-1331.9.s3.1.x (Pubitemid 35471977)
143. J Zoldan G Friedberg M Livneh E Melamed 1995 Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist Neurology 45 1305 1308 7617188 1:STN:280:DyaK2Mzkt1Cjtg%3D%3D
144. J Zoldan G Friedberg A Weizman E Melamed 1996 Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic l-DOPA therapy in advanced Parkinson's disease Adv Neurol 69 541 544 8615178 1:CAS:528:DyaK2sXmsFGqs7g%3D
145. B Ballanger AP Strafella T van Eimeren M Zurowski PM Rusjan S Houle SH Fox 2010 Serotonin 2A receptors and visual hallucinations in Parkinson disease Arch Neurol 67 416 421 20385906 10.1001/archneurol.2010.35
146. HY Meltzer R Mills S Revell H Williams A Johnson D Bahr JH Friedman 2010 Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis Neuropsychopharmacology 35 881 892 19907417 1:CAS:528:DC%2BC3cXhslOis7Y%3D 10.1038/npp.2009.176
147. JM Rabey 2009 Hallucinations and psychosis in Parkinson's disease Parkinsonism Relat Disord 15 S105 S110 20123547 10.1016/S1353-8020(09)70846-6
148. DM Weiner KE Vanover MR Brann HY Meltzer RE Davis 2003 Psychosis of Parkinson's disease: serotonin 2A inverse agonists as potential therapeutics Curr Opin Investig Drugs 4 815 819 14619402 1:CAS:528:DC%2BD3sXntVSrs7g%3D (Pubitemid 37265044)
149. G Meco P Stirpe F Edito C Purcaro M Valente S Bernardi N Vanacore 2009 Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study J Neural Transm 116 881 884 19533295 1:CAS:528:DC%2BD1MXns1ersrY%3D 10.1007/s00702-009-0231-z
150. KE Vanover AJ Betz SM Weber F Bibbiani A Kielaite DM Weiner RE Davis TN Chase JD Salamone 2008 A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model Pharmacol Biochem Behav 90 540 544 18534670 1:CAS:528:DC%2BD1cXhtVClurjP 10.1016/j.pbb.2008.04.010
151. MC Ferguson T Nayyar AY Deutch TA Ansah 2010 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease Neuropharmacology 59 31 36 20361986 1:CAS:528:DC%2BC3cXmslCmsrg%3D 10.1016/j.neuropharm.2010.03.013
152. AL Werneck AL Rosso MB Vincent 2009 The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson's disease Arq Neuropsiquiatr 67 407 412 19623435 10.1590/S0004-282X2009000300007
153. D Rylander M Parent SS O'Sullivan S Dovero AJ Lees E Bezard L Descarries MA Cenci 2010 Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann Neurol 68 619 628 20882603 1:CAS:528: DC%2BC3cXhsFOnsrnE 10.1002/ana.22097
154. BY Zeng MM Iravani MJ Jackson S Rose A Parent P Jenner 2010 Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Dis 40 599 607 20713157 1:CAS:528:DC%2BC3cXhtlSnurjP 10.1016/j.nbd.2010.08.004
155. A Berthet G Porras E Doudnikoff H Stark M Cador E Bezard B Bloch 2009 Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia J Neurosci 29 4829 4835 19369551 1:CAS:528:DC%2BD1MXltFShs7s%3D 10.1523/JNEUROSCI.5884-08.2009
156. B Picconi A Pisani I Barone P Bonsi D Centonze G Bernardi P Calabresi 2005 Pathological synaptic plasticity in the striatum: implications for Parkinson's disease Neurotoxicology 26 779 783 15927256 1:CAS:528: DC%2BD2MXhtFWhsLnI 10.1016/j.neuro.2005.02.002 (Pubitemid 41427517)
157. B Picconi V Ghiglieri P Calabresi 2010 L-3,4-Dihydroxyphenylalanine- indued sprouting of serotonin axon terminals: a useful biomarker for dyskinesias? Ann Neurol 68 578 580 21031574 1:CAS:528:DC%2BC3cXhsFOnsrnJ 10.1002/ana.22231
158. IA Prescott JO Dostrovsky E Moro M Hodaie AM Lozano WD Hutchison 2009 Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients Brain 132 309 318 19050033 1:STN:280: DC%2BD1M7jtVGrtw%3D%3D 10.1093/brain/awn322
159. P Krack W Hamel HM Mehdorn G Deuschl 1999 Surgical treatment of Parkinson's disease Curr Opin Neurol 12 417 425 10555830 1:STN:280: DC%2BD3c%2Fit1OmtA%3D%3D 10.1097/00019052-199908000-00008 (Pubitemid 30028739)
160. P Limousin P Krack P Pollak A Benazzouz C Ardouin D Hoffmann AL Benabid 1998 Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease N Engl J Med 339 1105 1111 9770557 1:STN:280:DyaK1cvjt1Cmsg%3D%3D 10.1056/NEJM199810153391603 (Pubitemid 28465758)
161. JA Obeso MC Rodriguez-Oroz M Rodriguez R Macias L Alvarez J Guridi J Vitek MR DeLong 2000 Pathophysiologic basis of surgery for Parkinson's disease Neurology 55 Suppl 6 S7 S12 11188978 1:STN:280:DC%2BD3M%2FpvVKqtA%3D%3D
162. ML Welter JL Houeto S Tezenas du Montcel V Mesnage AM Bonnet B Pillon I Arnulf B Pidoux D Dormont P Cornu Y Agid 2002 Clinical predictive factors of subthalamic stimulation in Parkinson's disease Brain 125 575 583 11872614 1:STN:280:DC%2BD387jslCisA%3D%3D 10.1093/brain/awf050 (Pubitemid 34194412)
163. AL Benabid S Chabardes E Seigneuret P Pollak V Fraix P Krack JF Lebas S Grand B Piallat 2005 Functional neurosurgery: past, present, and future Clin Neurosurg 52 265 270 16626081 1:STN:280:DC%2BD283hvFamtw%3D%3D
164. V Fraix P Pollak N Van Blercom J Xie P Krack A Koudsie AL Benabid 2000 Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease Neurology 26 1921 1923 (Pubitemid 32103981)
165. P Krack P Limousin AL Benabid P Pollak 1997 Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesia in Parkinson's disease Lancet 350 1676 9400515 1:STN:280:DyaK1c%2FmtlWlsA%3D%3D 10.1016/S0140-6736(05) 64273-0 (Pubitemid 28036831)
166. P Krack A Batir N Van Blercom, et al. 2003 Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease N Engl J Med 349 1925 1934 14614167 1:CAS:528:DC%2BD3sXptVGnurk%3D 10.1056/NEJMoa035275 (Pubitemid 37409709)
167. AL Benabid A Benazzouz P Pollak 2002 Mechanisms of deep brain stimulation Mov Disord 17 Suppl 3 S73 S74 11948758 10.1002/mds.10145 (Pubitemid 36040908)
168. JO Dostrovsky AM Lozano 2002 Mechanisms of deep brain stimulation Mov Disord 17 Suppl 3 S63 S68 11948756 10.1002/mds.10143
169. CC McIntyre M Savasta Kerkerian-Le GoffL JL Vitek 2004 Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both Clin Neurophysiol 115 1239 1248 15134690 10.1016/j.clinph.2003.12.024 (Pubitemid 38596707)
170. L Lopiano M Rizzone B Bergamasco A Tavella E Torre P Perozzo MC Valentini M Lanotte 2001 Deep brain stimulation of the subthalamic nucleus: clinical effectiveness and safety Neurology 27 552 554 (Pubitemid 32172888)
171. JL Molinuevo F Valldeoriola E Tolosa J Rumia J Valls-Sole H Roldan E Ferrer 2000 Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease Arch Neurol 57 983 988 10891980 1:STN:280:DC%2BD3czltF2msA%3D%3D 10.1001/archneur.57.7.983 (Pubitemid 30452503)
172. E Moro M Scerrati LM Romito R Roselli P Tonali A Albanese 1999 Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease Neurology 53 85 90 10408541 1:STN:280:DyaK1MzjsFShtA%3D%3D (Pubitemid 29329653)
173. A Oueslati V Sgambato-Faure C Melon P Kachidian P Gubellini M Amri L Kerkerian-Le Goff P Salin 2007 High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease J Neurosci 27 2377 2386 17329435 1:CAS:528:DC%2BD2sXjsVymsLg%3D 10.1523/JNEUROSCI.2949-06.2007 (Pubitemid 46340976)
174. C Simonin M Tir D Devos A Jreisler K Dujardin J Salleron A Delval S Blond L Defebvre A Destee P Krystkowiak 2009 Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon J Neurol 256 1736 1741 19536584 10.1007/s00415-009-5195-2
175. P Gubellini A Eusebio A Oueslati C Melon L Kerkerian-Le Goff P Salin 2006 Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission Eur J Neurosci 24 1802 1814 17004943 10.1111/j.1460-9568. 2006.05047.x (Pubitemid 44427549)
176. T Nimura K Yamaguchi T Ando S Shibuya T Oikawa A Nakagawa R Shirane M Itoh T Tominaga 2005 Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study J Neurosurg 103 968 973 16381182 1:CAS:528:DC%2BD2MXhtlelur3L 10.3171/jns.2005.103.6.0968 (Pubitemid 43194544)
177. E Lacombe C Carcenac S Boulet C Feurstein A Bertrand A Poupard M Savasta 2007 High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats Eur J Neurosci 26 1670 1680 17822436 10.1111/j.1460-9568.2007.05747.x (Pubitemid 47416512)
178. TA Zesiewicz RA Hauser 2002 Depression in Parkinson's disease Curr Psychiatry Rep 4 69 73 11814399 10.1007/s11920-002-0016-7
179. A Nieoullon 2002 Dopamine and the regulation of cognition and attention Prog Neurobiol 67 53 83 12126656 1:CAS:528:DC%2BD38Xlt1OitLc%3D 10.1016/S0301-0082(02)00011-4 (Pubitemid 34786170)
180. C Siri R Cilia D De Gaspari M Canesi N Meucci AL Zecchinelli G Pezzoli A Antonini 2010 Cognitive status of patients with Parkinson's disease and pathological gambling J Neurol 257 247 252 19727901 10.1007/s00415-009-5301-5
181. V Voon PO Fernagut J Wickens C Baunez M Rodriguez N Pavon JL Juncos JA Obeso E Bezard 2009 Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders Lancet Neurol 8 1140 1149 19909912 1:CAS:528:DC%2BD1MXhsFymsbzN 10.1016/S1474-4422(09)70287-X